Mixed Lineage Kinase
MLKs
Mixed lineage kinases (MLKs) are mitogen activated protein kinase kinase kinases (MAPKKKs) with features of both serine-threonine and tyrosine kinases that regulate the c-Jun N-terminal kinase (JNK) mitogen activated protein kinase (MAPK) signaling cascade, and also regulate p38 and extracellular signal-regulated kinase (ERK).
MLK3 (MAP3K11) is the most widely expressed MLK family member, and is expressed in neurons (as well as other cell types). At the cellular level, MLK3 is activated by stress, including reactive oxygen species, ceramide, and TNFα. At the molecular level, it is activated by Cdc42 and Rac, which interact with MLK3, and can cause it to dimerize via a leucine zipper interface, resulting in autophosphorylation and enzyme activation.
All Product Categories
-
Mixed Lineage Kinase Related Products (59)
Related Products (59)
-
Antibodies (3)
-
Biotin-MLK2 Recombinant Human Active Protein Kinase
0 ImagesCat. No.: HY-E70800MLK2 is a kinase for phosphorylation of H3 at threonine 3 and is associated with the osmotic stress response. MLK2 is involved in multiple signaling pathways in the developmental process. Biotin-MLK2 Recombinant Human Active Protein Kinase is obtained by expressing MLK2 proteins and is biotinylated.
-
MLKL-IN-3
0 ImagesCat. No.: HY-151541CAS No.: 3031406-27-3MLKL-IN-3 (compound 66) is a potent MLKL (Mixed lineage kinase domain-like protein) inhibitor. MLKL-IN-3 inhibits necroptosis in HT-29 cells and acts downstream of MLKL phosphorylation, with EC50 of 31 nM. MLKL-IN-3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
-
PROTAC MLKL Degrader-3
0 ImagesCat. No.: HY-182343PROTAC MLKL Degrader-3 is a MLKL PROTAC degrader with DC50 values of 248.9 nM (Hepa1-6) and 271.3 nM (HepG2), respectively. PROTAC MLKL Degrader-3 induces proteasome- and cereblon-dependent MLKL degradation via ubiquitination. PROTAC MLKL Degrader-3 reduces intratumoral MLKL levels and inhibits tumor growth in mice. PROTAC MLKL Degrader-3 can be used in the research of hepatocellular carcinoma.
-
RIPK1-IN-42
0 ImagesCat. No.: HY-184686RIPK1-IN-42 is an orally active RIPK1 inhibitor with a Kd of 21 nM. RIPK1-IN-42 inhibits the phosphorylation of RIPK1, suppresses the phosphorylation of downstream RIPK3 and MLKL, blocks necrosome formation, and inhibits necroptosis. RIPK1-IN-42 alleviates hypothermia, suppresses the elevation of pro-inflammatory cytokine levels, and reduces organ damage. RIPK1-IN-42 can be used for the research of systemic inflammatory response syndrome.
-
WJH-C19
0 ImagesCat. No.: HY-181596Purity: 98.65%WJH-C19 is an orally active RIPK1 inhibitor with an IC50 of 5.7 nM. WJH-C19 inhibits the RIPK1/RIPK3/MLKL signaling axis, blocks RIPK1 phosphorylation, suppresses the phosphorylation of downstream RIPK3 and MLKL, disrupts necrosome formation, and exhibits protective effects against necroptosis (Apoptosis) in multiple cell lines. WJH-C19 ameliorates symptoms of inflammatory bowel disease in a mouse colitis model by regulating the necroptosis pathway. WJH-C19 alleviates inflammation and bone destruction in a mouse model of rheumatoid arthritis. WJH-C19 is applicable to research related to inflammatory bowel disease and rheumatoid arthritis.
-
MLKL-IN-5
0 ImagesCat. No.: HY-148767CAS No.: 2755872-58-1MLKL-IN-5 is a mixed lineage kinase domain-like protein (MLKL) inhibitor with a KD of < 10 nM. MLKL-IN-5 exhibits selectivity for RIP3 and RIP1, with KD values of 1-30 μM and > 30 μM, respectively. MLKL-IN-5 mediates necroptosis.
-
MLKL-IN-7
0 ImagesCat. No.: HY-161361CAS No.: 3034839-17-0MLKL-IN-7 (compound 9) is a MLKL inhibitor, and shows anti-necroptosis activity in HT-29 cells with the IC50 of 148.4 nM.
-
MLKL-IN-1
0 ImagesCat. No.: HY-139878CAS No.: 2837019-30-2MLKL-IN-1 is a covalent MLKL inhibitor with a KD of 50 μM.
-
MLKL ligand-2
0 ImagesCat. No.: HY-182344MLKL ligand-2 is a mixed lineage kinase domain-like pseudokinase (MLKL) PROTAC ligand with a KD of 9.408 μM. MLKL ligand-2 forms hydrogen bond networks and hydrophobic interactions with specific MLKL residues, and stabilizes MLKL in hepatic cells. MLKL ligand-2 can be used to synthesize PROTAC MLKL Degrader-3 (HY-182343).
-
MLK-IN-3
0 ImagesCat. No.: HY-180338CAS No.: 105788-15-6MLK-IN-3 (Compound 30) is a MLK inhibitor with an IC50 of less than 5 μM. MLK-IN-3 can be used in the research of neurological diseases.
-
Anticancer agent 267
0 ImagesCat. No.: HY-173075Anticancer agent 267 (Compound 5q) is the activator for RIPK3 and MLKL. Anticancer agent 267 inhibits the proliferation in a variety of cancer cell lines (IC50 for MDA-MB-231, MDA-MB-486 and MCF-7 is 9.79, 10.77 and 5.94 μM, respectively), arrests cell cycle at subG1 phase, and induces necroptosis in cell MDA-MB-231. Anticancer agent 267 exhibits antitumor activity in mouse xenograft models.
-
PROTAC MLKL Degrader-2
0 ImagesCat. No.: HY-169072CAS No.: 3103327-20-1PROTAC MLKL Degrader-2 is an orally active and highly selective mixed lineage kinase domain-like pseudokinase (MLKL) PROTAC degrader with a DC50 of 0.012 μM. PROTAC MLKL Degrader-2 recruits the CRBN E3 ubiquitin ligase to form a ternary complex, leading to ubiquitination of MLKL and its degradation via a proteasome-dependent pathway. PROTAC MLKL Degrader-2 inhibits necroptosis, reduces ROS production, restores mitochondrial function, and ameliorates lysosomal dysfunction induced by necroptotic stimuli. PROTAC MLKL Degrader-2 degrades MLKL in xenograft mouse models. PROTAC MLKL Degrader-2 can be used in cancer-related research.
-
Biotin-MLK1 Recombinant Human Active Protein Kinase
0 ImagesCat. No.: HY-E70799MLK1 is a kinase for phosphorylation of H3 at threonine 3 and is associated with the osmotic stress response. MLK1 is involved in multiple signaling pathways in the developmental process. Biotin-MLK1 Recombinant Human Active Protein Kinase is obtained by expressing MLK1 proteins and is biotinylated.
-
MLKL-IN-4
0 ImagesCat. No.: HY-151542CAS No.: 3031406-17-1MLKL-IN-4 (compound 56) is a potent MLKL (Mixed lineage kinase domain-like protein) inhibitor. MLKL-IN-4 inhibits necroptosis in HT-29 cells and acts downstream of MLKL phosphorylation, with EC50 of 82 nM. MLKL-IN-4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
-
Ligustroflavone (Standard)
0 ImagesCat. No.: HY-N0546RCAS No.: 260413-62-5Synonyms: Nuezhenoside (Standard)Ligustroflavone (Standard) is the analytical standard of Ligustroflavone (HY-N0546). This product is intended for research and analytical applications. Ligustroflavone is an orally active flavonoid compound. Ligustroflavone can be extracted from Ligustrum lucidum. Ligustroflavone antagonizes the calcium-sensing receptor (CaSR), inhibits the RIPK1/RIPK3/MLKL pathway, and downregulates TGF-β/Smad signaling. Ligustroflavone regulates calcium metabolism, protects bone tissue, reduces cerebral ischemic injury, and inhibits liver fibrosis. Ligustroflavone can be used in the study of diabetic osteoporosis, ischemic stroke, and liver fibrosis.
-
Necrosulfonamide (Standard)
0 ImagesCat. No.: HY-100573RCAS No.: 1360614-48-7Necrosulfonamide (Standard) is the analytical standard of Necrosulfonamide (HY-100573). This product is intended for research and analytical applications. Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways.
-
TC13172 (Standard)
0 ImagesCat. No.: HY-101524RCAS No.: 2093393-05-4
-
MLK-IN-1 (Standard)
0 ImagesCat. No.: HY-111351RCAS No.: 1627729-62-7
